Treatment of Cancer of Unknown Primary Site with Sintilimab Combined with Anlotinib: A Case Report
Abstract：Cancer of unknown primary site (CUP) is a highly heterogeneous tumor that is diagnosed as metastatic malignant tumor by histopathological examination, but the primary site cannot be identified through systematic clinical examination, accounting for 3% to 5% of all malignant tumors [1].
Keywords：Cancer of unknown primary siteImmunotherapy
Publication Date：2025-01-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 102-104 )